0001108205-26-000061
SEC filingQ1 2026 delivered no revenue following the Erivedge sale, with operating and net losses widening due to increased general and administrative expenses from the January PIPE financing and heightened cash burn from payment timing, underscoring urgent funding needs for emavusertib development.
Curis reported no revenue in Q1 FY2026, a complete drop from $2.4 million in the prior year quarter, reflecting the impact of the November 2025 sale of Erivedge to TPC Investments Royalty LLC (Oberland) for upfront consideration and royalty liability release. This transaction eliminated the prior revenue base, aligning with the company's strategic pivot to focus resources on emavusertib development.
Operating income deteriorated to -$11.5 million from -$10.2 million year-over-year. Management attributes the increase in general and administrative expenses primarily to costs associated with the January 2026 PIPE financing, partially offset by lower employee-related costs. This dynamic highlights the trade-offs of securing capital through equity offerings amid ongoing clinical advancement.
Net income swung to a deeper loss of -$24.2 million compared to -$10.6 million last year, with diluted EPS stable at -$1.25. The widened net loss reflects the combined pressures of higher operating costs and financing-related expenses, consistent with the company's clinical-stage biotech profile where development investments outpace near-term revenues.
Looking forward, Curis expects to continue generating substantial operating losses and incurring significant capital expenditures to develop and commercialize emavusertib, including support for research and development activities and licensing obligations under the Aurigene collaboration. The company will require substantial additional capital in the immediate term to fund emavusertib's further development and general and administrative costs. These planned requirements signal sustained investment in the pipeline, particularly for ongoing trials in PCNSL/ibrutinib and CLL/zanubrutinib combinations, while navigating liquidity constraints post-Erivedge divestiture and PIPE activities.
Overall, the quarter underscores Curis's transition to a pure-play development-stage entity, where clinical progress drives expense growth and necessitates ongoing financing efforts to sustain operations through key milestones.